Navigation Links
DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Company's Scientific Advisory Board
Date:6/3/2008

LA JOLLA, Calif., June 3 /PRNewswire/ -- DermTech, a biotechnology company developing molecular diagnostics for the early detection of melanoma and other diseases, today announced that Herbert A. Fritsche, Ph.D., has joined DermTech's Scientific Advisory Board. Dr. Fritsche is Professor and Chief of Clinical Chemistry at M.D. Anderson Cancer Center and one of the world's experts in the development and validation of cancer diagnostics for early disease detection and in the fast-growing area of translational research, moving research into clinical practice.

"We are honored that Dr. Fritsche is joining DermTech's Scientific Advisory Board and we are delighted to welcome him to the company," said George Schwartz, CEO, DermTech. "Dr. Fritsche has been with M.D. Anderson for almost 40 years and is one of the pioneers of today's molecular diagnostic assays for cancer detection and predicting drug response. His expertise will clearly be a major asset to DermTech as we are moving forward at an accelerated pace to develop our first product for the non-invasive early detection of melanoma."

"I am very pleased to become a member of DermTech's SAB and assist the company as it continues to optimize its novel melanoma assay and develops additional diagnostics using its "tape stripping" technology for the early detection of disease," said Herbert A. Fritsche, Ph.D. "This is an exciting time in medicine - in the field of cancer, I predict that within 10 years and maybe less, no major treatment decisions will be made without first consulting a laboratory test. I am looking forward to applying my experience to what I believe will be the next-generation approach to improved cancer detection."

Dr. Fritsche's career at M.D. Anderson includes some of the earliest work in translational research including the development of blood and tissue tests for protein tumor markers (CEA, AFP, HCG, LDH, B2M, estrogen and progesterone receptors), more recently, tests for circulating DNA (promoter regions of tumor suppressor genes for prostate cancer detection), urine mRNA survivin for bladder cancer detection and circulating tumor cell assays for establishing prognosis of patients with metastatic cancers.

Dr. Fritsche received his B.S. from the University of Houston (Chemistry), and M.S. and Ph.D. from Texas A & M University. Additionally, as Captain, Medical Service Corps, he completed a two-year assignment at the First US Army Medical Laboratory at Ft. Meade, MD before joining the faculty of the University of Texas MD Anderson Cancer Center.

About DermTech:

Headquartered in La Jolla, California, DermTech International is focused on the development and validation of molecular tests using specimens obtained from the skin. The company's proprietary Epidermal Genetic Information Retrieval (EGIR(TM)) technology is in clinical studies to evaluate its potential as a non-invasive diagnostic for melanoma and other major diseases. It is also being studied in the context of tracking treatment efficacy for a variety of dermatologic and other conditions, including the effects of drugs on skin at the molecular level in advance of observable clinical results. DermTech is actively pursuing research using EGIR(TM) and its applications in the areas of melanoma, prostate cancer and various skin disorders, such as psoriasis. For additional information visit http://www.dermtech.com.

Contacts:

DermTech

George Schwartz, CEO

858.450.4222

For DermTech

Jennifer Larson

415.409.2729

jlarson@labfive.com


'/>"/>
SOURCE DermTech
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR
2. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
3. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
4. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
5. Abt Associates Names Richard Small Vice President and Chief Financial Officer
6. Premier Research Names Anthony Faragasso, MD as Executive Director and Global Head of Medical Management and Safety
7. Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise
8. Gene Network Sciences Names New CSO and Announces New Scientific Advisory Board
9. RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
10. Codexis Names David Anton VP Bioindustrials R&D
11. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... DC (PRWEB) , ... July 18, 2017 , ... ... the Allotrope Framework, and has released the first phase of the Allotrope Framework ... World’s Best Practices Awards were created to “not only elevate the critical role ...
(Date:7/17/2017)... ... ... The Academy of Model Aeronautics (AMA) will host Aviation Adventure Day on August ... 9 a.m. to 2 p.m. at the International Aeromodeling Center in Muncie, Indiana. The ... will be packed with entertaining activities for the entire family. Attendees will learn while ...
(Date:7/17/2017)... ... July 17, 2017 , ... Neurodevelopmental disorders (NDDs) are ... overlapping clinical features. The advancement of targeted next-generation sequencing (NGS) has been instrumental ... testing. , However, designing a custom panel for disease research requires hours ...
(Date:7/17/2017)... ... 17, 2017 , ... DuPont Pioneer today announced the launch ... (openinnovation.pioneer.com) dedicated to connecting third-party innovators with DuPont Pioneer scientists is now available ... biologicals and digital solutions. , “DuPont Pioneer is building on its long history ...
Breaking Biology Technology:
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):